Response to Crizotinib After Entrectinib Resistance in ROS1-Rearranged, MET-Amplified Lung Adenocarcinoma

JCO Precis Oncol. 2024 Oct:8:e2400394. doi: 10.1200/PO-24-00394. Epub 2024 Oct 7.

Authors

Affiliations

¹ Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA.
² Harvard Medical School, Boston, MA.
³ Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY.
⁴ Department of Pathology, Brigham and Women's Hospital, Boston, MA.

PMID: 39374479
DOI: 10.1200/PO-24-00394

Abstract

Crizotinib successfully overcomes MET amplification in ROS1-rearranged NSCLC after entrectinib failure.

Publication types

Case Reports

MeSH terms

Adenocarcinoma of Lung* / drug therapy
Adenocarcinoma of Lung* / genetics
Benzamides* / therapeutic use
Crizotinib* / therapeutic use
Drug Resistance, Neoplasm* / genetics
Female
Gene Rearrangement
Humans
Indazoles* / therapeutic use
Lung Neoplasms* / drug therapy
Lung Neoplasms* / genetics
Male
Protein Kinase Inhibitors / therapeutic use
Protein-Tyrosine Kinases* / genetics
Proto-Oncogene Proteins c-met* / genetics
Proto-Oncogene Proteins* / genetics

Substances

Crizotinib
ROS1 protein, human
Proto-Oncogene Proteins
Indazoles
entrectinib
Protein-Tyrosine Kinases
Proto-Oncogene Proteins c-met
Benzamides
MET protein, human
Protein Kinase Inhibitors